	US 12,109,177 B2
	Neutrophil suppression as preconditioning to increase oncolytic bacterial therapy
Renyuan Bai, Baltimore, MD (US); and Verena Staedtke, Baltimore, MD (US)
Assigned to The Johns Hopkins University, Baltimore, MD (US)
Filed by The Johns Hopkins University, Baltimore, MD (US)
Filed on Dec. 20, 2022, as Appl. No. 18/085,467.
Claims priority of provisional application 63/294,320, filed on Dec. 28, 2021.
Prior Publication US 2023/0201137 A1, Jun. 29, 2023
Int. Cl. A61K 31/133 (2006.01); A61K 31/535 (2006.01); A61K 35/742 (2015.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01)

CPC A61K 31/133 (2013.01) [A61K 31/535 (2013.01); A61K 35/742 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01)]

11 Claims

1. A method of treating a solid tumor in a subject comprising:

(a) administering to the subject at least one immunoregulatory compound selected from at least one of an anti-neutrophil antibody, hydroxyurea, or cyclophosphamide; and

(b) administering at least one anaerobic species of bacteria,

wherein the at least one immunoregulatory compound is administered prior to administering the anaerobic species of bacteria,

thereby treating the solid tumor in the subject.